BCR-ABL/ABL RATIO INCREASE THAT CORRESPONDS TOPRESENCEOFBCR-ABL MUTATION IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED BY IMATINIB

被引：0

作者：

Tsaur, G. ^{[1
]}

Ivanova, A. ^{[1
]}

Popov, A. ^{[1
]}

Yakovleva, Y. ^{[1
]}

Riger, T. ^{[1
]}

Ivanets, Y. ^{[2
]}

Misyurin, A. ^{[3
]}

Suchkova, M. ^{[3
]}

Shorikov, E. ^{[1
]}

Saveliev, L. ^{[4
]}

Fechina, L. ^{[1
]}

机构：

[1] Reg Childrens Hosp, Res Inst Med Cell Technol, Pediat Oncol & Hematol Ctr, Ekaterinburg, Russia

[2] Novartis Pharmaceut, BU Oncol, Ekaterinburg, Russia

[3] Minist Publ Hlth Russia, Hematol Res Ctr, Lab Gene Engn, Moscow, Russia

[4] Ural State Med Acad, Chair Lab Med, Ekaterinburg, Russia

来源：

CLINICAL CHEMISTRY AND LABORATORY MEDICINE | 2011年 / 49卷

关键词：

D O I：

暂无

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

引用

页码：S490 / S490

页数：1

共 50 条

[21] Response to Imatinib Treatment in Chronic Myeloid Leukemia According to BCR-ABL Transcript
Acosta Hernandez, Titania del Carmen
Best Aguilera, Carlos Roberto
Villela Martinez, Luis Mario
Guzman Hernandez, Alicia Elizabeth
Robles Rodriguez, Arianna
Lopez Hernandez, Juan Carlos
Gomez Vazquez, Oscar Rodrigo
Rivera Mendoza, Laura Adriana
Garcia Reyes, Barbara
Gutierrez Alatorre, Aldo Fernando Adrian
Calderon Valdez, Areli Sarai
Visuetti Pimentel, Saribethe Mahely
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S242 - S243
[22] Inadequate BCR-ABL monitoring in imatinib-treated patients with chronic myelogenous leukemia
Stanek, E.
Aubert, R. E.
Sanders, C.
Frueh, F. W.
Yao, J.
Epstein, R. S.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[23] BCR-ABL monitoring in imatinib-treated patients with chronic myelogenous leukemia.
Teitelbaum, A. H.
Henk, H. J.
Bollu, V.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[24] Cantharidin Overcomes Imatinib Resistance by Depleting BCR-ABL in Chronic Myeloid Leukemia
Sun, Xiaoyan
Cai, Xueting
Yang, Jie
Chen, Jiao
Guo, Caixia
Cao, Peng
MOLECULES AND CELLS, 2016, 39 (12) : 869 - 876
[25] Detection of BCR-ABL T315i Mutation in Imatinib Resistant Chronic Myeloid Leukemia Patients
Mardziah, M.
Salwati, S.
Azlin, I
Hafiza, A.
Farisah, Noor A. R.
Noraesah, M.
Tumian, N. R.
Wong, C. L.
Azma, R. Z.
MEDICINE AND HEALTH-KUALA LUMPUR, 2019, 14 (01): : 145 - 156
[26] BCR-ABL KINASE DOMAIN MUTATION FREQUENCY IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS RESISTANT TO IMATINIB THERAPY
Tikhonova, V.
Misyurina, E.
Kesaeva, L.
Finashutina, Y.
Krutov, A.
Aksenova, E.
Soldatova, I.
Soldatkina, O.
Ivanova, V.
Novitskaya, N.
Arshanskaya, E.
Lazarev, I.
Volkova, M.
Pospelova, T.
Konstantinova, T.
Vysotskaya, L.
Voloditcheva, E.
Lapin, V.
Davydkin, I.
Turkina, A.
Kolosheinova, T.
Goryacheva, S.
Chelysheva, E.
Pristupa, A.
Golubenko, R.
Gavrilova, L.
Volkova, S.
Kuchma, G.
Ovsyannikova, E.
Zaklyakova, L.
Kaplanov, K.
Klitochenko, T.
Misyurin, A.
HAEMATOLOGICA, 2013, 98 : 548 - 548
[27] Serial but not single BCR-ABL transcript rises are predictive of ABL kinase mutations in chronic myeloid leukaemia patients treated by imatinib
Wang, L
Knight, K
Lucas, CM
Clark, RE
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 : 33 - 33
[28] New BCR-ABL inhibitors in chronic myeloid leukemia
Rea, Delphine
ANNALS OF ONCOLOGY, 2019, 30
[29] Mutant BCR-ABL clones in chronic myeloid leukemia
Mathisen, Michael S.
Kantarjian, Hagop M.
Cortes, Jorge
Jabbour, Elias
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (03): : 347 - 349
[30] OUTCOME OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA WITH T3151 BCR-ABL MUTATION
De Souza, C. A.
Pagnano, K. B. B.
Silveira, R. A.
Nardinelli, L.
Mello, M.
De Souza, C.
Dorliac, P. H.
Lorand-Metze, I.
Funcke, V.
Zanichelli, M. A.
Clementino, N.
Pasquini, R.
Bendit, I.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 434 - 434

← 1 2 3 4 5 →